These findings support a role for CCR2+ monocytes in PD-related neuroinflammation and highlight the need for future longitudinal studies to track dopaminergic therapy initiation, dosage, and regimen changes to clarify its influence on monocyte phenotypes and their association with disease progression. This evidence concerns the gene CCR2 and Parkinson disease.